Please login to the form below

Not currently logged in
Email:
Password:

axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

CMS proposes coverage scheme for CAR-T therapies

CMS proposes coverage scheme for CAR-T therapies

Sciences’ Yescarta (axicabtagene ciloleucel) given the nod shortly afterwards for various forms of non-Hodgkin’s lymphoma (NHL) including DLBCL.

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics